Glochidonol

Glochidonol

SCHEMBL3740114

C=C(C)[C@@H]1CC[C@]2(C)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)[C@H](O)CC(=O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]12

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 4/20 0.60
TOP2A P11388 2/20 0.60
CES2 O00748 2/20 0.60
CES1 P23141 2/20 0.60
PTGES O14684 2/20 0.58
LMNA P02545 3/20 0.52
NT5E P21589 3/20 0.52
GPBAR1 Q8TDU6 3/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
GLI1 P08151 3/20 0.50
MAPT P10636 1/20 0.50
ATM Q13315 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
ALB P02768 2/20 0.46
USP2 O75604 2/20 0.46
HIF1A Q16665 2/20 0.46
AKR1B10 O60218 1/20 0.46
POLB P06746 1/20 0.46
AKR1B1 P15121 1/20 0.46
DPP4 P27487 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27953264 0.83 PTPN1 (0.46) PTPN1TOP2ACES2CES1PTGES
SCHEMBL18668382 0.82 GPBAR1 (0.46) PTPN1TOP2ACES2CES1PTGES
Lupenone SCHEMBL27218586 0.81 GPBAR1 (0.75) PTPN1TOP2ACES2CES1PTGES
Lupenone SCHEMBL13692854 0.81 GPBAR1 (0.75) PTPN1TOP2ACES2CES1PTGES
Lupenone SCHEMBL13908727 0.81 GPBAR1 (0.75) PTPN1TOP2ACES2CES1PTGES
Lupenone SCHEMBL13908802 0.81 GPBAR1 (0.75) PTPN1TOP2ACES2CES1PTGES
Lupenone SCHEMBL13851777 0.81 GPBAR1 (0.75) PTPN1TOP2ACES2CES1PTGES
Lupenone SCHEMBL1224027 0.81 GPBAR1 (0.75) PTPN1TOP2ACES2CES1PTGES
Glochidiol SCHEMBL31237879 0.81 PTPN1 (0.71) PTPN1TOP2ACES2CES1PTGES
SCHEMBL17124246 0.78 PTPN1 (0.63) PTPN1TOP2ACES2CES1PTGES

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104274831-A Composition based on naturally derived peptide and inflammation inhibitor and/or anti-oxidation compound SOO TUCK POOI 2015-01-14 CN claimed
CN-104274831-A Composition based on naturally derived peptide and inflammation inhibitor and/or anti-oxidation compound SOO TUCK POOI 2015-01-14 CN disclosed
EP-1395270-B1 USE OF PHYLLANTHUS COMPONENTS FOR PREPARATION OF A MEDICAMENT FOR THE PREVENTION OR TREATMENT OF INFECTIONS CAUSED BY RESISTANT HEPATITIS B VIRUS PHYTRIX AG (DE) 2014-07-23 EP disclosed
US-7829124-B2 Use of Phyllanthus constituents for treating or preventing infections caused by hepatitis B-viruses OTT MICHAEL 2010-11-09 US disclosed
US-20070264359-A1 administering an effective amount of an aqueous or alcohol extract of Phyllanthus to a mammal infected with the YMDD hepatitis B virus mutant strain resistant; inhibiting viral gene expression in a mammal infected with a hepatitis B virus OTT MICHEAL 2007-11-15 US disclosed
US-20040197426-A1 inhibition of the amplification of a hepatitis B virus resistant to nucleoside analogues (Lamivudine and Famciclovir) OTT MICHAEL (DE) 2004-10-07 US disclosed
EP-1395270-A1 USE OF PHYLLANTHUS CONSTITUENTS FOR TREATING OR PREVENTING INFECTIONS CAUSED BY HEPATIT Phytrix AG (DE) 2004-03-10 EP disclosed
US-20040028754-A1 Use of phyllanthus component for the treatment or prophylaxis of infections triggered by flaviviridae VON KEUDELL CHRISTOPH (DE) 2004-02-12 US disclosed
EP-1294387-A2 USE OF PHYLLANTHUS CONSTITUENTS FOR TREATING OR PREVENTING INFECTIONS CAUSED BY FLAVIVIRIDAE CMI-Centers for Medical Innovation AG (DE) 2003-03-26 EP disclosed
WO-2002087600-A1 USE OF PHYLLANTHUS CONSTITUENTS FOR TREATING OR PREVENTING INFECTIONS CAUSED BY HEPATIT PHYTRIX AG (DE) 2002-11-07 WO disclosed
US-20020054921-A1 The extract form the plant genus Phyllanthus belongs to the subfamily of Phyllantoideae which belong to the family of Euphoribiaceae, contacted to the viruses belonging to the family of Flaviviridae CMI CENTERS FOR MEDICAL INOVATION AG (DE) 2002-05-09 US disclosed
WO-2001097824-A2 USE OF PHYLLANTHUS CONSTITUENTS FOR TREATING OR PREVENTING INFECTIONS CAUSED BY FLAVIVIRIDAE CMI-CENTERS FOR MEDICAL INNOVATION AG (DE) 2001-12-27 WO disclosed